Prab: CSV import

2025-02-20T00:59:27Z

CSV import

← Older revision		Revision as of 00:59, 20 February 2025
Line 32:		Line 32:
	[[Category:Janus kinase inhibitors]]		[[Category:Janus kinase inhibitors]]
	[[Category:Experimental drugs]]		[[Category:Experimental drugs]]
			<gallery>
			File:Decernotinib.svg\|Decernotinib
			</gallery>

Prab: CSV import

2025-02-13T03:55:31Z

CSV import

← Older revision		Revision as of 03:55, 13 February 2025
Line 1:		Line 1:
	~~'''~~Decernotinib~~''' is an experimental drug that was under development for the treatment of [[rheumatoid arthritis]]~~. ~~It is a selective inhibitor~~ of ~~[[Janus kinase 3]] (JAK3), a protein that plays a crucial role in the immune response.~~ Decernotinib ~~was developed by [[Vertex Pharmaceuticals]] but its development was discontinued in 2016 due to safety concerns.~~		{{Short description\|Overview of the drug Decernotinib}}
			{{Drugbox
			\| verifiedfields = changed
			\| verifiedrevid = 477002123
			\| image = Decernotinib.svg
			\| image_size = 200px
			\| image_alt = Chemical structure of Decernotinib
			}}

	~~== Mechanism~~ of ~~Action ==~~		'''Decernotinib''' is a [[Janus kinase inhibitor]] (JAK inhibitor) that has been investigated for its potential use in the treatment of [[rheumatoid arthritis]]. It specifically targets the JAK3 enzyme, which plays a crucial role in the signaling pathways of various cytokines involved in the immune response.

	Decernotinib ~~works~~ by selectively inhibiting the activity of JAK3. ~~This protein~~ is ~~involved in~~ the signaling ~~pathways~~ of ~~various [[cytokines]]~~ and ~~[[growth factors]] that are important for immune response~~. By inhibiting JAK3, decernotinib ~~reduces~~ the inflammatory response that ~~is characteristic of~~ rheumatoid arthritis.		==Mechanism of Action==
			Decernotinib functions by selectively inhibiting the activity of the [[Janus kinase 3\|JAK3]] enzyme. JAK3 is associated with the common gamma chain of cytokine receptors, which are critical for the signaling of several interleukins, including IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. By inhibiting JAK3, decernotinib disrupts these signaling pathways, leading to a reduction in the inflammatory response that characterizes autoimmune diseases such as rheumatoid arthritis.

	== Clinical ~~Trials~~ ==		==Clinical Development==
			Decernotinib has undergone various phases of clinical trials to assess its efficacy and safety in patients with rheumatoid arthritis. These trials have focused on its ability to reduce the symptoms of the disease, such as joint pain and swelling, and to improve overall physical function.

	~~Several [[clinical trials]] were conducted to evaluate the safety and efficacy~~ of decernotinib ~~in patients with rheumatoid arthritis~~. ~~However, the development of the~~ drug ~~was discontinued~~ in ~~2016 due to safety concerns~~.		==Pharmacokinetics==
			The pharmacokinetic profile of decernotinib includes its absorption, distribution, metabolism, and excretion. It is administered orally and has been shown to have a predictable absorption pattern. The drug is metabolized primarily in the liver and excreted through both renal and fecal pathways.

	== ~~Safety Concerns~~ ==		==Side Effects==
			Common side effects observed in clinical trials of decernotinib include [[headache]], [[nausea]], and [[upper respiratory tract infection]]. As with other JAK inhibitors, there is a potential risk of serious infections due to the suppression of the immune system.

	~~The development~~ of decernotinib ~~was discontinued due to safety concerns~~. ~~In clinical trials, some patients experienced serious adverse events, including infections~~ and ~~changes in liver function tests. The risk of these adverse events was considered to outweigh the potential benefits of the drug~~.		==Potential Applications==
			While primarily investigated for rheumatoid arthritis, the mechanism of action of decernotinib suggests potential applications in other autoimmune diseases where JAK3 plays a role. These could include conditions such as [[psoriasis]] and [[inflammatory bowel disease]].

	== ~~See Also~~ ==		==Related pages==

	* [[Janus kinase inhibitor]]
	* [[Rheumatoid arthritis]]		* [[Rheumatoid arthritis]]
	* [[~~Vertex Pharmaceuticals~~]]		* [[Janus kinase inhibitors]]
			* [[Autoimmune disease]]
	~~== References ==~~

	~~<references />~~

			[[Category:Janus kinase inhibitors]]
	[[Category:Experimental drugs]]		[[Category:Experimental drugs]]
	~~[[Category:Janus kinase inhibitors]]~~
	~~[[Category:Rheumatoid arthritis]]~~
	~~{{stub}}~~

Prab: CSV import

2024-02-22T15:33:56Z

CSV import

New page

'''Decernotinib''' is an experimental drug that was under development for the treatment of [[rheumatoid arthritis]]. It is a selective inhibitor of [[Janus kinase 3]] (JAK3), a protein that plays a crucial role in the immune response. Decernotinib was developed by [[Vertex Pharmaceuticals]] but its development was discontinued in 2016 due to safety concerns.

== Mechanism of Action ==

Decernotinib works by selectively inhibiting the activity of JAK3. This protein is involved in the signaling pathways of various [[cytokines]] and [[growth factors]] that are important for immune response. By inhibiting JAK3, decernotinib reduces the inflammatory response that is characteristic of rheumatoid arthritis.

== Clinical Trials ==

Several [[clinical trials]] were conducted to evaluate the safety and efficacy of decernotinib in patients with rheumatoid arthritis. However, the development of the drug was discontinued in 2016 due to safety concerns.

== Safety Concerns ==

The development of decernotinib was discontinued due to safety concerns. In clinical trials, some patients experienced serious adverse events, including infections and changes in liver function tests. The risk of these adverse events was considered to outweigh the potential benefits of the drug.

== See Also ==

* [[Janus kinase inhibitor]]
* [[Rheumatoid arthritis]]
* [[Vertex Pharmaceuticals]]

== References ==

<references />

[[Category:Experimental drugs]]
[[Category:Janus kinase inhibitors]]
[[Category:Rheumatoid arthritis]]
{{stub}}

Decernotinib - Revision history

Prab: CSV import

Prab: CSV import

Prab: CSV import